Hangzhou Tigermed Consulting Co., Ltd.
HNGZY · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $6,603,120 | $7,384,039 | $7,085,471 | $5,213,538 |
| % Growth | -10.6% | 4.2% | 35.9% | – |
| Cost of Goods Sold | $4,361,107 | $4,535,511 | $4,277,008 | $2,942,883 |
| Gross Profit | $2,242,013 | $2,848,529 | $2,808,464 | $2,270,655 |
| % Margin | 34% | 38.6% | 39.6% | 43.6% |
| R&D Expenses | $238,386 | $261,555 | $234,619 | $211,829 |
| G&A Expenses | $300,503 | $259,931 | $256,060 | $244,025 |
| SG&A Expenses | $349,253 | $306,723 | $405,951 | $373,424 |
| Sales & Mktg Exp. | $48,750 | $46,792 | $149,890 | $129,399 |
| Other Operating Expenses | $989,955 | -$209,861 | $357,120 | $307,514 |
| Operating Expenses | $1,577,594 | $358,417 | $997,690 | $892,767 |
| Operating Income | $664,419 | $2,486,941 | $2,582,399 | $1,919,043 |
| % Margin | 10.1% | 33.7% | 36.4% | 36.8% |
| Other Income/Exp. Net | $42 | $1,593 | $2,979 | $1,765,523 |
| Pre-Tax Income | $664,462 | $2,488,533 | $2,585,377 | $3,684,566 |
| Tax Expense | $216,630 | $338,606 | $313,652 | $292,864 |
| Net Income | $405,143 | $2,024,850 | $2,006,552 | $2,874,163 |
| % Margin | 6.1% | 27.4% | 28.3% | 55.1% |
| EPS | 0.47 | 2.34 | 2.32 | 3.31 |
| % Growth | -79.9% | 0.9% | -29.9% | – |
| EPS Diluted | 0.47 | 2.34 | 2.32 | 3.3 |
| Weighted Avg Shares Out | 862,007 | 865,321 | 864,893 | 868,327 |
| Weighted Avg Shares Out Dil | 862,007 | 864,949 | 864,893 | 870,958 |
| Supplemental Information | – | – | – | – |
| Interest Income | $90,219 | $229,849 | $227,338 | $255,877 |
| Interest Expense | $141,235 | $124,134 | $83,179 | $24,910 |
| Depreciation & Amortization | $324,140 | $339,023 | $284,845 | $196,763 |
| EBITDA | $1,129,837 | $2,846,507 | $2,953,401 | $3,894,660 |
| % Margin | 17.1% | 38.5% | 41.7% | 74.7% |